{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:40:18Z","timestamp":1787161218735,"version":"build-2736575974"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170865"],"award-info":[{"award-number":["82170865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202211365"],"award-info":[{"award-number":["tsqn202211365"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10157-023-02413-2","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:02:10Z","timestamp":1697511730000},"page":"125-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances"],"prefix":"10.1007","volume":"28","author":[{"given":"Xinping","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxia","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7775-2823","authenticated-orcid":false,"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5232-7913","authenticated-orcid":false,"given":"Zhentao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2413_CR1","doi-asserted-by":"publisher","first-page":"ii121","DOI":"10.1093\/ndt\/gfw330","volume":"32","author":"KJ Jager","year":"2017","unstructured":"Jager KJ, Fraser S. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol Dial Transplant. 2017;32:ii121\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2413_CR2","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238\u201352.","journal-title":"Lancet"},{"key":"2413_CR3","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709\u201333."},{"key":"2413_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","volume":"382","author":"KU Eckardt","year":"2013","unstructured":"Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158\u201369.","journal-title":"Lancet"},{"key":"2413_CR5","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322:1294\u2013304.","journal-title":"JAMA"},{"key":"2413_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/dom.14801","volume":"24","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao L, Mi Y, He W. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Obes Metab. 2022;24:2159\u201368.","journal-title":"Diabetes Obes Metab"},{"key":"2413_CR7","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","volume":"6","author":"PI Georgianos","year":"2021","unstructured":"Georgianos PI, Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2021;6:2281\u201391.","journal-title":"Kidney Int Rep"},{"key":"2413_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","volume":"18","author":"AB van der Aart-van der Beek","year":"2022","unstructured":"van der Aart-van der Beek AB, de Boer RA, Heerspink H. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18:294\u2013306.","journal-title":"Nat Rev Nephrol"},{"key":"2413_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11906-017-0771-9","volume":"19","author":"F Zhang","year":"2017","unstructured":"Zhang F, Liu H, Liu D, et al. Effects of RAAS inhibitors in patients with kidney disease. Curr Hypertens Rep. 2017;19:72.","journal-title":"Curr Hypertens Rep"},{"key":"2413_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385\u2013403.","journal-title":"ChemMedChem"},{"key":"2413_CR11","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125\u201340.","journal-title":"J Endocrinol"},{"key":"2413_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271\u2013305.","journal-title":"Handb Exp Pharmacol"},{"key":"2413_CR13","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179:3220\u201334.","journal-title":"Br J Pharmacol"},{"key":"2413_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101386","volume":"47","author":"D Parfianowicz","year":"2022","unstructured":"Parfianowicz D, Shah S, Nguyen C, et al. Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection. Curr Probl Cardiol. 2022;47: 101386.","journal-title":"Curr Probl Cardiol"},{"key":"2413_CR15","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.05012","volume":"5","author":"S Viengchareun","year":"2007","unstructured":"Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lomb\u00e8s M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5: e012.","journal-title":"Nucl Recept Signal"},{"key":"2413_CR16","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1210\/en.2010-0465","volume":"151","author":"Funder JW","year":"2010","unstructured":"Funder JW. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology. 2010;151:5098\u2013102.","journal-title":"Endocrinology"},{"key":"2413_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.phrs.2016.03.037","volume":"107","author":"MH de Borst","year":"2016","unstructured":"de Borst MH, Navis G. Sodium intake, RAAS-blockade and progressive renal disease. Pharmacol Res. 2016;107:344\u201351.","journal-title":"Pharmacol Res"},{"key":"2413_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","volume":"42","author":"A Nishiyama","year":"2019","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42:293\u2013300.","journal-title":"Hypertens Res"},{"key":"2413_CR19","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","volume":"43","author":"A Verma","year":"2022","unstructured":"Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022;43:3781\u201391.","journal-title":"Eur Heart J"},{"key":"2413_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","volume":"58","author":"AS Brem","year":"2011","unstructured":"Brem AS, Morris DJ, Gong R. Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis. 2011;58:471\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2413_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1046\/j.1523-1755.2000.00976.x","volume":"57","author":"N Farman","year":"2000","unstructured":"Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int. 2000;57:1364\u20139.","journal-title":"Kidney Int"},{"key":"2413_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCRESAHA.120.317424","volume":"127","author":"A Lother","year":"2020","unstructured":"Lother A. Mineralocorticoid receptors: master regulators of extracellular matrix remodeling. Circ Res. 2020;127:354\u20136.","journal-title":"Circ Res"},{"key":"2413_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.859812","volume":"13","author":"R Palacios-Ramirez","year":"2022","unstructured":"Palacios-Ramirez R, Lima-Posada I, Bonnard B, et al. Mineralocorticoid receptor antagonism prevents the synergistic effect of metabolic challenge and chronic kidney disease on renal fibrosis and inflammation in mice. Front Physiol. 2022;13: 859812.","journal-title":"Front Physiol"},{"key":"2413_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948658","volume":"13","author":"P Qiang","year":"2022","unstructured":"Qiang P, Hao J, Yang F, et al. Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor\/TGF-\u03b21 pathway in mice induced with aldosterone. Front Immunol. 2022;13: 948658.","journal-title":"Front Immunol"},{"key":"2413_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34:15\u201327.","journal-title":"Am J Hypertens"},{"issue":"12","key":"2413_CR26","first-page":"63","volume":"2022","author":"JM Luther","year":"2011","unstructured":"Luther JM, Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int Suppl. 2011;2022(12):63\u20138.","journal-title":"Kidney Int Suppl"},{"key":"2413_CR27","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bph.15734","volume":"179","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Jaisser F, Anders HJ. The mineralocorticoid receptor in chronic kidney disease. Br J Pharmacol. 2022;179:3152\u201364.","journal-title":"Br J Pharmacol"},{"key":"2413_CR28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","volume":"37","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022;37:1014\u201323.","journal-title":"Nephrol Dial Transplant"},{"key":"2413_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","volume":"22","author":"JS Rico-Mesa","year":"2020","unstructured":"Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep. 2020;22:140.","journal-title":"Curr Cardiol Rep"},{"key":"2413_CR30","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37:2105\u201314.","journal-title":"Eur Heart J"},{"key":"2413_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143:540\u201352.","journal-title":"Circulation"},{"key":"2413_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall D, Jacobs N, Mahfoud F, Kolkhof P, B\u00f6hm M, Laufs U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol. 2019;168:173\u201383.","journal-title":"Biochem Pharmacol"},{"key":"2413_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000524940","volume":"53","author":"K Luettges","year":"2022","unstructured":"Luettges K, Bode M, Diemer JN, et al. Finerenone Reduces renal ROR\u03b3t \u03b3\u03b4 T cells and protects against cardiorenal damage. Am J Nephrol. 2022;53:552\u201364.","journal-title":"Am J Nephrol"},{"key":"2413_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","volume":"67","author":"A Gueret","year":"2016","unstructured":"Gueret A, Harouki N, Favre J, et al. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension. 2016;67:717\u201323.","journal-title":"Hypertension"},{"key":"2413_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","volume":"121","author":"B Bonnard","year":"2018","unstructured":"Bonnard B, Pieronne-Deperrois M, Djerada Z, et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol. 2018;121:124\u201333.","journal-title":"J Mol Cell Cardiol"},{"key":"2413_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nrd1039","volume":"2","author":"R Brown","year":"2003","unstructured":"Brown R, Quirk J, Kirkpatrick P. Eplerenone. Nat Rev Drug Discov. 2003;2:177\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"2413_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0002-8703(78)90052-2","volume":"96","author":"HR Ochs","year":"1978","unstructured":"Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Spironolactone. Am Heart J. 1978;96:389\u2013400.","journal-title":"Am Heart J"},{"key":"2413_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","volume":"18","author":"H Haller","year":"2016","unstructured":"Haller H, Bertram A, Stahl K, Menne J. Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD. Curr Hypertens Rep. 2016;18:41.","journal-title":"Curr Hypertens Rep"},{"key":"2413_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5:488\u2013501.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2413_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-021-01082-2","volume":"61","author":"P van den Berg","year":"2022","unstructured":"van den Berg P, Ruppert M, Mesic E, et al. Finerenone dose-exposure-response for the primary kidney outcome in FIDELIO-DKD phase III: population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet. 2022;61:439\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"2413_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone-results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30:172\u201384.","journal-title":"Fundam Clin Pharmacol"},{"key":"2413_CR42","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, In Vivo and In Vitro. Drug Metab Dispos. 2018;46:1546\u201355.","journal-title":"Drug Metab Dispos"},{"key":"2413_CR43","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C] eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31:1448\u201355.","journal-title":"Drug Metab Dispos"},{"key":"2413_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29:342\u20137.","journal-title":"J Clin Pharmacol"},{"key":"2413_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","volume":"16","author":"MI Danjuma","year":"2014","unstructured":"Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014;16:414.","journal-title":"Curr Hypertens Rep"},{"key":"2413_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"2413_CR47","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, Le Billan F, Kolkhof P, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290:21876\u201389.","journal-title":"J Biol Chem"},{"key":"2413_CR48","doi-asserted-by":"publisher","first-page":"e21314","DOI":"10.1096\/fj.202002043RR","volume":"35","author":"F Le Billan","year":"2021","unstructured":"Le Billan F, Perrot J, Carceller E, et al. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J. 2021;35:e21314.","journal-title":"FASEB J"},{"key":"2413_CR49","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","volume":"9","author":"R Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","unstructured":"Gonz\u00e1lez-Bl\u00e1zquez R, Somoza B, Gil-Ortega M, et al. Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol. 2018;9:1131.","journal-title":"Front Pharmacol"},{"key":"2413_CR50","first-page":"CD007004","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung EY, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020;10:CD007004.","journal-title":"Cochrane Database Syst Rev"},{"key":"2413_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40262-021-01083-1","volume":"61","author":"SC Goulooze","year":"2022","unstructured":"Goulooze SC, Snelder N, Seelmann A, et al. Finerenone dose-exposure-serum potassium response analysis of FIDELIO-DKD phase III: the role of dosing, titration, and inclusion criteria. Clin Pharmacokinet. 2022;61:451\u201362.","journal-title":"Clin Pharmacokinet"},{"key":"2413_CR52","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","volume":"39","author":"A Mima","year":"2022","unstructured":"Mima A. A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther. 2022;39:3488\u2013500.","journal-title":"Adv Ther"},{"key":"2413_CR53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther. 2022;7:182.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2413_CR54","first-page":"69","volume":"2022","author":"M Epstein","year":"2011","unstructured":"Epstein M. Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts. Kidney Int Suppl. 2011;2022(12):69\u201375.","journal-title":"Kidney Int Suppl"},{"key":"2413_CR55","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69:870\u20138.","journal-title":"Hypertension"},{"key":"2413_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12882-017-0490-0","volume":"18","author":"SG Mansour","year":"2017","unstructured":"Mansour SG, Puthumana J, Coca SG, Gentry M, Parikh CR. Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review. BMC Nephrol. 2017;18:72.","journal-title":"BMC Nephrol"},{"key":"2413_CR57","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000518254","volume":"52","author":"K Droebner","year":"2021","unstructured":"Droebner K, Pavkovic M, Grundmann M, et al. Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis. Am J Nephrol. 2021;52:588\u2013601.","journal-title":"Am J Nephrol"},{"key":"2413_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","volume":"589","author":"C Kuppe","year":"2021","unstructured":"Kuppe C, Ibrahim MM, Kranz J, et al. Decoding myofibroblast origins in human kidney fibrosis. Nature. 2021;589:281\u20136.","journal-title":"Nature"},{"key":"2413_CR59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62:237\u201344.","journal-title":"Kidney Int"},{"key":"2413_CR60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2008.01.020","volume":"52","author":"D Bolignano","year":"2008","unstructured":"Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52:595\u2013605.","journal-title":"Am J Kidney Dis"},{"key":"2413_CR61","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","volume":"70","author":"E Mart\u00ednez-Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez-Mart\u00ednez E, Buonafine M, Boukhalfa I, et al. Aldosterone target NGAL (Neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NF\u03baB pathway. Hypertension. 2017;70:1148\u201356.","journal-title":"Hypertension"},{"key":"2413_CR62","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41581-022-00590-z","volume":"18","author":"L Li","year":"2022","unstructured":"Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol. 2022;18:545\u201357.","journal-title":"Nat Rev Nephrol"},{"key":"2413_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1681\/ASN.2011070645","volume":"23","author":"J Chen","year":"2012","unstructured":"Chen J, Chen JK, Nagai K, et al. EGFR signaling promotes TGF\u03b2-dependent renal fibrosis. J Am Soc Nephrol. 2012;23:215\u201324.","journal-title":"J Am Soc Nephrol"},{"key":"2413_CR64","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1097\/01.ASN.0000098681.56240.1A","volume":"14","author":"Z Wang","year":"2003","unstructured":"Wang Z, Chen JK, Wang SW, Moeckel G, Harris RC. Importance of functional EGF receptors in recovery from acute nephrotoxic injury. J Am Soc Nephrol. 2003;14:3147\u201354.","journal-title":"J Am Soc Nephrol"},{"key":"2413_CR65","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/ki.2012.435","volume":"83","author":"J Tang","year":"2013","unstructured":"Tang J, Liu N, Zhuang S. Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int. 2013;83:804\u201310.","journal-title":"Kidney Int"},{"key":"2413_CR66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ajpath.2013.04.005","volume":"183","author":"J Tang","year":"2013","unstructured":"Tang J, Liu N, Tolbert E, et al. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol. 2013;183:160\u201372.","journal-title":"Am J Pathol"},{"key":"2413_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/248563","volume":"2013","author":"A Mima","year":"2013","unstructured":"Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013;2013: 248563.","journal-title":"J Diabetes Res"},{"key":"2413_CR68","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/2211-5463.12400","volume":"8","author":"A Mima","year":"2018","unstructured":"Mima A, Yasuzawa T, King GL, Ueshima S. Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio. 2018;8:664\u201370.","journal-title":"FEBS Open Bio"},{"key":"2413_CR69","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.semnephrol.2012.07.010","volume":"32","author":"A Mima","year":"2012","unstructured":"Mima A, Qi W, King GL. Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin Nephrol. 2012;32:471\u20138.","journal-title":"Semin Nephrol"},{"key":"2413_CR70","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41581-019-0158-z","volume":"15","author":"T Komada","year":"2019","unstructured":"Komada T, Muruve DA. The role of inflammasomes in kidney disease. Nat Rev Nephrol. 2019;15:501\u201320.","journal-title":"Nat Rev Nephrol"},{"key":"2413_CR71","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93:1344\u201355.","journal-title":"Kidney Int"},{"key":"2413_CR72","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1681\/ASN.2012111094","volume":"25","author":"LL Huang","year":"2014","unstructured":"Huang LL, Nikolic-Paterson DJ, Han Y, et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol. 2014;25:2231\u201340.","journal-title":"J Am Soc Nephrol"},{"key":"2413_CR73","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Rosenkranz K, Kusunoki Y, et al. Finerenone added to RAS\/SGLT2 blockade for CKD in alport syndrome. Results of a randomized controlled trial with Col4a3-\/-mice. J Am Soc Nephrol. 2023;34:1513\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"2413_CR74","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3390\/ijms24032334","volume":"24","author":"JR Jerome","year":"2023","unstructured":"Jerome JR, Deliyanti D, Suphapimol V, Kolkhof P, Wilkinson-Berka JL. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces vascular injury and increases regulatory t-cells: studies in rodents with diabetic and neovascular retinopathy. Int J Mol Sci. 2023;24:2334.","journal-title":"Int J Mol Sci"},{"key":"2413_CR75","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/978-981-13-8871-2_18","volume":"1165","author":"XM Meng","year":"2019","unstructured":"Meng XM. Inflammatory mediators and renal fibrosis. Adv Exp Med Biol. 2019;1165:381\u2013406.","journal-title":"Adv Exp Med Biol"},{"key":"2413_CR76","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/ndt\/gfy246","volume":"34","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Rocha L, Amador-Mart\u00ednez I, et al. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. Nephrol Dial Transplant. 2019;34:794\u2013801.","journal-title":"Nephrol Dial Transplant"},{"key":"2413_CR77","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/ijms21030725","volume":"21","author":"A Gluba-Brz\u00f3zka","year":"2020","unstructured":"Gluba-Brz\u00f3zka A, Franczyk B, Olszewski R, Rysz J. The influence of inflammation on anemia in CKD patients. Int J Mol Sci. 2020;21:725.","journal-title":"Int J Mol Sci"},{"key":"2413_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184888","volume":"12","author":"J Dutzmann","year":"2017","unstructured":"Dutzmann J, Musmann RJ, Haertl\u00e9 M, et al. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE. 2017;12: e0184888.","journal-title":"PLoS ONE"},{"key":"2413_CR79","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41598-020-62579-7","volume":"10","author":"A Mima","year":"2020","unstructured":"Mima A, Yasuzawa T, Nakamura T, Ueshima S. Linagliptin affects IRS1\/Akt signaling and prevents high glucose-induced apoptosis in podocytes. Sci Rep. 2020;10:5775.","journal-title":"Sci Rep"},{"key":"2413_CR80","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/ki.2010.526","volume":"79","author":"A Mima","year":"2011","unstructured":"Mima A, Ohshiro Y, Kitada M, et al. Glomerular-specific protein kinase C-\u03b2-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int. 2011;79:883\u201396.","journal-title":"Kidney Int"},{"key":"2413_CR81","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2413_CR82","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1152\/ajprenal.00340.2016","volume":"311","author":"B Spoto","year":"2016","unstructured":"Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016;311:1087\u2013108.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2413_CR83","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.3390\/nu13093138","volume":"13","author":"Z Kochan","year":"2021","unstructured":"Kochan Z, Szupryczynska N, Malgorzewicz S, Karbowska J. Dietary lipids and dyslipidemia in chronic kidney disease. Nutrients. 2021;13:3138.","journal-title":"Nutrients"},{"key":"2413_CR84","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jacc.2019.07.037","volume":"74","author":"F Emanuelsson","year":"2019","unstructured":"Emanuelsson F, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Benn M. Impact of LDL cholesterol on microvascular versus macrovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2019;74:1465\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"2413_CR85","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","volume":"15","author":"T Jin","year":"2023","unstructured":"Jin T, Fu X, Liu M, An F. Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus. Diabetol Metab Syndr. 2023;15:87.","journal-title":"Diabetol Metab Syndr"},{"key":"2413_CR86","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1210\/endrev\/bnaa017","volume":"41","author":"RJ Galindo","year":"2020","unstructured":"Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;41:756\u201374.","journal-title":"Endocr Rev"},{"key":"2413_CR87","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A Hirata","year":"2009","unstructured":"Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res. 2009;84:164\u201372.","journal-title":"Cardiovasc Res"},{"key":"2413_CR88","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/ehf2.13219","volume":"8","author":"M Pieronne-Deperrois","year":"2021","unstructured":"Pieronne-Deperrois M, Gu\u00e9ret A, Djerada Z, et al. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail. 2021;8:1933\u201343.","journal-title":"ESC Heart Fail"},{"key":"2413_CR89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11154-016-9402-z","volume":"18","author":"MR Hager","year":"2017","unstructured":"Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18:29\u201340.","journal-title":"Rev Endocr Metab Disord"},{"key":"2413_CR90","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1096\/fj.202000164R","volume":"34","author":"V Marzolla","year":"2020","unstructured":"Marzolla V, Feraco A, Gorini S, et al. The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. FASEB J. 2020;34:12450\u201365.","journal-title":"FASEB J"},{"key":"2413_CR91","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","volume":"45","author":"V Marzolla","year":"2022","unstructured":"Marzolla V, Feraco A, Limana F, Kolkhof P, Armani A, Caprio M. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest. 2022;45:215\u201320.","journal-title":"J Endocrinol Invest"},{"key":"2413_CR92","first-page":"1663","volume":"12","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Vordoni A, Kalaitzidis RG. Oxidative stress management in cardiorenal diseases: focus on novel antidiabetic agents, finerenone, and melatonin. Life (Basel). 2022;12:1663.","journal-title":"Life (Basel)."},{"key":"2413_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.909569","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Yang M, Li L, et al. A glimpse of inflammation and anti-inflammation therapy in diabetic kidney disease. Front Physiol. 2022;13: 909569.","journal-title":"Front Physiol"},{"key":"2413_CR94","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.2016040477","volume":"28","author":"J Barrera-Chimal","year":"2017","unstructured":"Barrera-Chimal J, Andr\u00e9-Gr\u00e9goire G, Nguyen Dinh Cat A, et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle rac1. J Am Soc Nephrol. 2017;28:1216\u201326.","journal-title":"J Am Soc Nephrol"},{"key":"2413_CR95","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"key":"2413_CR96","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ejhf.218","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Anker SD, B\u00f6hm M, et al. Rationale and design of mineralocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease. Eur J Heart Fail. 2015;17:224\u201332.","journal-title":"Eur J Heart Fail"},{"key":"2413_CR97","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"2413_CR98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","volume":"41","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41:295\u2013302.","journal-title":"J Hypertens"},{"key":"2413_CR99","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s11255-022-03432-w","volume":"55","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Song M, Chen T, Yang Z, Liu Y. Effect of finerenone on cardiovascular events in kidney disease and\/or diabetes: a meta analysis of randomized control trials. Int Urol Nephrol. 2023;55:1373\u201381.","journal-title":"Int Urol Nephrol"},{"key":"2413_CR100","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2413_CR101","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1111\/dom.15197","volume":"25","author":"P Rossing","year":"2023","unstructured":"Rossing P, Anker SD, Filippatos G, et al. The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: post hoc analysis of the FIDELITY study. Diabetes Obes Metab. 2023;25:2989\u201398.","journal-title":"Diabetes Obes Metab"},{"key":"2413_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192895","volume":"13","author":"RW Major","year":"2018","unstructured":"Major RW, Cheng M, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2018;13: e0192895.","journal-title":"PLoS ONE"},{"key":"2413_CR103","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2413_CR104","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","volume":"78","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Bakris GL, Pitt B, et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol. 2021;78:142\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"2413_CR105","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ehjcvp\/pvad001","volume":"9","author":"G Filippatos","year":"2023","unstructured":"Filippatos G, Anker SD, August P, et al. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023;9:183\u201391.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2413_CR106","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2413_CR107","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33:225\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"2413_CR108","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211\u201321.","journal-title":"N Engl J Med"},{"key":"2413_CR109","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372:222\u201331.","journal-title":"N Engl J Med"},{"key":"2413_CR110","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1\u2013S87.","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"2413_CR111","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/dom.14696","volume":"24","author":"RA DeFronzo","year":"2022","unstructured":"DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022;24:1197\u2013205.","journal-title":"Diabetes Obes Metab"},{"key":"2413_CR112","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","volume":"32","author":"A Mima","year":"2018","unstructured":"Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complicat. 2018;32:720\u20135.","journal-title":"J Diabetes Complicat"},{"key":"2413_CR113","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s12325-021-01735-5","volume":"38","author":"A Mima","year":"2021","unstructured":"Mima A. Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease. Adv Ther. 2021;38:2201\u201312.","journal-title":"Adv Ther"},{"key":"2413_CR114","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"2413_CR115","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148\u201358.","journal-title":"JAMA Cardiol"},{"key":"2413_CR116","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","volume":"84","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Bonnard B, Jaisser F. Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases. Annu Rev Physiol. 2022;84:585\u2013610.","journal-title":"Annu Rev Physiol"},{"key":"2413_CR117","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","volume":"37","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Anker SD, Filippatos G, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022;37:1261\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2413_CR118","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.14558","volume":"24","author":"P Rossing","year":"2022","unstructured":"Rossing P, Agarwal R, Anker SD, et al. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022;24:125\u201334.","journal-title":"Diabetes Obes Metab"},{"key":"2413_CR119","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dom.14883","volume":"25","author":"P Rossing","year":"2023","unstructured":"Rossing P, Agarwal R, Anker SD, et al. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023;25:407\u201316.","journal-title":"Diabetes Obes Metab"},{"key":"2413_CR120","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease-mechanistic and therapeutic effects. Nat Rev Nephrol. 2022;18:56\u201370.","journal-title":"Nat Rev Nephrol"},{"key":"2413_CR121","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1152\/ajpendo.00022.2023","volume":"324","author":"L Yao","year":"2023","unstructured":"Yao L, Liang X, Wang P. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease. Am J Physiol Endocrinol Metab. 2023;324:531\u201341.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2413_CR122","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.kint.2023.03.037","volume":"104","author":"H Heerspink","year":"2023","unstructured":"Heerspink H, Jongs N, Neuen BL, et al. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023;104:181\u20138.","journal-title":"Kidney Int"},{"key":"2413_CR123","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","volume":"79","author":"L Tu","year":"2022","unstructured":"Tu L, Thuillet R, Perrot J, et al. Mineralocorticoid receptor antagonism by finerenone attenuates established pulmonary hypertension in rats. Hypertension. 2022;79:2262\u201373.","journal-title":"Hypertension"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02413-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T21:10:17Z","timestamp":1706130617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02413-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2413"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02413-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}